Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/15/2025 | $65.00 | Outperform | Exane BNP Paribas |
3/21/2025 | $65.00 | Neutral | Goldman |
1/30/2025 | Sell → Hold | Deutsche Bank | |
7/26/2024 | $55.00 → $60.00 | Buy | Argus |
1/23/2024 | $55.00 | Equal-Weight | Morgan Stanley |
1/16/2024 | Buy | UBS | |
12/5/2023 | Overweight → Neutral | JP Morgan | |
10/30/2023 | Buy → Hold | Stifel |
New fund supports nonprofit partners working to address social drivers of health and strengthen community well-beingCAMBRIDGE, Mass., June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and well-being in historically undersupported communities. The initiative is part of Sanofi's broader commitment to improve equitable access to healthcare by addressing structural factors, such as lack of access to housing, food, and behavioral health. Launched earlier this year, the Fund strategically inves
TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU